111 Capital’s Neurocrine Biosciences NBIX Stock Holding History

111 Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,628	Closed	-$443K	–	696
2026 Q2	$443K	Buy	+2,628	New	+$390K	0.08%	262
2025 Q4	–	Sell	-1,738	Closed	-$244K	–	471
2025 Q3	$244K	Buy	+1,738	New	+$235K	0.05%	362

Other funds holding NBIX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

111 Capital's NBIX Position: Q3 2026 in Review

111 Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 2,628 shares — an estimated $443K sold.

111 Capital first reported a position in NBIX in Q3 2025 and held it in 2 quarters. The position peaked at $443K in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

111 Capital reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
111 Capital sold 2,628 Neurocrine Biosciences shares in Q3 2026, an estimated $443K.
111 Capital first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 2 quarters.
111 Capital's Neurocrine Biosciences position peaked at $443K in Q2 2026.
630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on 111 Capital's 13F filing for Q3 2026, filed 3 Nov 2026.